Skip to main content
PMC home page
Infection and Immunity logoLink to Infection and Immunity
. 1996 Aug;64(8):3360–3368. doi: 10.1128/iai.64.8.3360-3368.1996

Distinct characteristics of initiation of the classical and alternative complement pathways by Candida albicans.

T R Kozel 1, L C Weinhold 1, D M Lupan 1
PMCID: PMC174230  PMID: 8757876

Abstract

Candida albicans is a potent activator of the complement system. The objective of this study was to characterize factors that influence the kinetics for activation of C3 and binding of C3 fragments to C. albicans. Factors that were examined included the surface properties of the yeast and contributions of the classical and alternative complement pathways. The results showed that incubation of hydrophobic, hydrophilic, or germinating yeast cells in normal human serum (NHS) containing radiolabeled C3 led to immediate accumulation of C3 on all three cell types, although the rate of accumulation of C3 on germinating cells was lower. An examination of the sites for early C3 binding showed that classical pathway initiation led to immediate, synchronous binding over the entire cell surface. A blockade of the classical pathway by absorption of putative classical pathway initiators or by chelation of calcium limited activation to the alternative pathway. Binding of C3 solely via the alternative pathway was characterized by a significant lag in the initial binding kinetics. In the absence of classical pathway initiation, the early cellular sites for C3 binding appeared as random, asynchronous foci of C3 that appeared to expand with time. The factor(s) mediating rapid deposition of C3 that was characteristic of the classical pathway initiation was reciprocally cross-absorbed by hydrophilic and hydrophobic C. albicans but was not removed by absorption of NHS with Saccharomyces cerevisiae, encapsulated Cryptococcus neoformans, or nonencapsulated C. neoformans. Delayed binding of C3 produced by absorption of serum was largely reversed by addition to the absorbed serum of immunoglobulin G isolated from NHS, indicating a significant role for a naturally occurring anti-C. albicans immunoglobulin C. in classical pathway initiation.

Full Text

The Full Text of this article is available as a PDF (498.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. BLUM L. EVIDENCE FOR IMMUNOLOGICAL SPECIFICITY OF THE PROPERDIN SYSTEM; DEMONSTRATION, ISOLATION AND PROPERTIES OF A SERUM FACTOR WHICH INTERACTS WITH ZYMOSAN AND OTHER POLYSACCHARIDES AT 0 DEGREES CENTIGRADE. J Immunol. 1964 Jan;92:61–72. [PubMed] [Google Scholar]
  2. Cutler J. E., Kanbe T. Antigenic variability of Candida albicans cell surface. Curr Top Med Mycol. 1993;5:27–47. [PubMed] [Google Scholar]
  3. Edwards J. E., Jr, Gaither T. A., O'Shea J. J., Rotrosen D., Lawley T. J., Wright S. A., Frank M. M., Green I. Expression of specific binding sites on Candida with functional and antigenic characteristics of human complement receptors. J Immunol. 1986 Dec 1;137(11):3577–3583. [PubMed] [Google Scholar]
  4. Eigentler A., Schulz T. F., Larcher C., Breitwieser E. M., Myones B. L., Petzer A. L., Dierich M. P. C3bi-binding protein on Candida albicans: temperature-dependent expression and relationship to human complement receptor type 3. Infect Immun. 1989 Feb;57(2):616–622. doi: 10.1128/iai.57.2.616-622.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Fine D. P., Marney S. R., Jr, Colley D. G., Sergent J. S., Des Prez R. M. C3 shunt activation in human serum chelated with EGTA. J Immunol. 1972 Oct;109(4):807–809. [PubMed] [Google Scholar]
  6. Fraker P. J., Speck J. C., Jr Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphrenylglycoluril. Biochem Biophys Res Commun. 1978 Feb 28;80(4):849–857. doi: 10.1016/0006-291x(78)91322-0. [DOI] [PubMed] [Google Scholar]
  7. Gelfand J. A., Hurley D. L., Fauci A. S., Frank M. M. Role of complement in host defense against experimental disseminated candidiasis. J Infect Dis. 1978 Jul;138(1):9–16. doi: 10.1093/infdis/138.1.9. [DOI] [PubMed] [Google Scholar]
  8. Greenfield R. A., Bussey M. J., Stephens J. L., Jones J. M. Serial enzyme-linked immunosorbent assays for antibody to Candida antigens during induction chemotherapy for acute leukemia. J Infect Dis. 1983 Aug;148(2):275–283. doi: 10.1093/infdis/148.2.275. [DOI] [PubMed] [Google Scholar]
  9. Greenfield R. A., Stephens J. L., Bussey M. J., Jones J. M. Quantitation of antibody to Candida mannan by enzyme-linked immunosorbent assay. J Lab Clin Med. 1983 May;101(5):758–771. [PubMed] [Google Scholar]
  10. Han Y., Cutler J. E. Antibody response that protects against disseminated candidiasis. Infect Immun. 1995 Jul;63(7):2714–2719. doi: 10.1128/iai.63.7.2714-2719.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Hazen K. C., Brawner D. L., Riesselman M. H., Jutila M. A., Cutler J. E. Differential adherence of hydrophobic and hydrophilic Candida albicans yeast cells to mouse tissues. Infect Immun. 1991 Mar;59(3):907–912. doi: 10.1128/iai.59.3.907-912.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Hazen K. C., Glee P. M. Hydrophobic cell wall protein glycosylation by the pathogenic fungus Candida albicans. Can J Microbiol. 1994 Apr;40(4):266–272. doi: 10.1139/m94-043. [DOI] [PubMed] [Google Scholar]
  13. Hazen K. C., Hazen B. W. Hydrophobic surface protein masking by the opportunistic fungal pathogen Candida albicans. Infect Immun. 1992 Apr;60(4):1499–1508. doi: 10.1128/iai.60.4.1499-1508.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Hazen K. C., Hazen B. W. Surface hydrophobic and hydrophilic protein alterations in Candida albicans. FEMS Microbiol Lett. 1993 Feb 15;107(1):83–87. doi: 10.1111/j.1574-6968.1993.tb06008.x. [DOI] [PubMed] [Google Scholar]
  15. Hector R. F., Domer J. E., Carrow E. W. Immune responses to Candida albicans in genetically distinct mice. Infect Immun. 1982 Dec;38(3):1020–1028. doi: 10.1128/iai.38.3.1020-1028.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Heidenreich F., Dierich M. P. Candida albicans and Candida stellatoidea, in contrast to other Candida species, bind iC3b and C3d but not C3b. Infect Immun. 1985 Nov;50(2):598–600. doi: 10.1128/iai.50.2.598-600.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Ikeda K., Sannoh T., Kawasaki N., Kawasaki T., Yamashina I. Serum lectin with known structure activates complement through the classical pathway. J Biol Chem. 1987 Jun 5;262(16):7451–7454. [PubMed] [Google Scholar]
  18. James P. G., Cherniak R., Jones R. G., Stortz C. A., Reiss E. Cell-wall glucans of Cryptococcus neoformans Cap 67. Carbohydr Res. 1990 Apr 2;198(1):23–38. doi: 10.1016/0008-6215(90)84273-w. [DOI] [PubMed] [Google Scholar]
  19. Jones J. M. Quantitation of antibody against cell wall mannan and a major cytoplasmic antigen of Candida in rabbits, mice, and humans. Infect Immun. 1980 Oct;30(1):78–89. doi: 10.1128/iai.30.1.78-89.1980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Keller R. G., Pfrommer G. S., Kozel T. R. Occurrences, specificities, and functions of ubiquitous antibodies in human serum that are reactive with the Cryptococcus neoformans cell wall. Infect Immun. 1994 Jan;62(1):215–220. doi: 10.1128/iai.62.1.215-220.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Kocourek J., Ballou C. E. Method for fingerprinting yeast cell wall mannans. J Bacteriol. 1969 Dec;100(3):1175–1181. doi: 10.1128/jb.100.3.1175-1181.1969. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Kozel T. R., Brown R. R., Pfrommer G. S. Activation and binding of C3 by Candida albicans. Infect Immun. 1987 Aug;55(8):1890–1894. doi: 10.1128/iai.55.8.1890-1894.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Kozel T. R., Pfrommer G. S., Guerlain A. S., Highison B. A., Highison G. J. Strain variation in phagocytosis of Cryptococcus neoformans: dissociation of susceptibility to phagocytosis from activation and binding of opsonic fragments of C3. Infect Immun. 1988 Nov;56(11):2794–2800. doi: 10.1128/iai.56.11.2794-2800.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Kozel T. R., Wilson M. A., Pfrommer G. S., Schlageter A. M. Activation and binding of opsonic fragments of C3 on encapsulated Cryptococcus neoformans by using an alternative complement pathway reconstituted from six isolated proteins. Infect Immun. 1989 Jul;57(7):1922–1927. doi: 10.1128/iai.57.7.1922-1927.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Kozel T. R., Wilson M. A., Welch W. H. Kinetic analysis of the amplification phase for activation and binding of C3 to encapsulated and nonencapsulated Cryptococcus neoformans. Infect Immun. 1992 Aug;60(8):3122–3127. doi: 10.1128/iai.60.8.3122-3127.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Lehmann P. F., Reiss E. Comparison by ELISA of serum anti-Candida albicans mannan IgG levels of a normal population and in diseased patients. Mycopathologia. 1980 Mar 17;70(2):89–93. doi: 10.1007/BF00443073. [DOI] [PubMed] [Google Scholar]
  27. Lu J. H., Thiel S., Wiedemann H., Timpl R., Reid K. B. Binding of the pentamer/hexamer forms of mannan-binding protein to zymosan activates the proenzyme C1r2C1s2 complex, of the classical pathway of complement, without involvement of C1q. J Immunol. 1990 Mar 15;144(6):2287–2294. [PubMed] [Google Scholar]
  28. Morelli R., Rosenberg L. T. Role of complement during experimental Candida infection in mice. Infect Immun. 1971 Apr;3(4):521–523. doi: 10.1128/iai.3.4.521-523.1971. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Morelli R., Rosenberg L. T. The role of complement in the phagocytosis of Candida albicans by mouse peripheral blood leukocytes. J Immunol. 1971 Aug;107(2):476–480. [PubMed] [Google Scholar]
  30. Morrison R. P., Cutler J. E. In vitro studies of the interaction of murine phagocytic cells with Candida albicans. J Reticuloendothel Soc. 1981 Jan;29(1):23–34. [PubMed] [Google Scholar]
  31. Ohta M., Okada M., Yamashina I., Kawasaki T. The mechanism of carbohydrate-mediated complement activation by the serum mannan-binding protein. J Biol Chem. 1990 Feb 5;265(4):1980–1984. [PubMed] [Google Scholar]
  32. Platts-Mills T. A., Ishizaka K. Activation of the alternate pathway of human complements by rabbit cells. J Immunol. 1974 Jul;113(1):348–358. [PubMed] [Google Scholar]
  33. Poulain D., Tronchin G., Dubremetz J. F., Biguet J. Ultrastructure of the cell wall of Candida albicans blastospores: study of its constitutive layers by the use of a cytochemical technique revealing polysaccharides. Ann Microbiol (Paris) 1978 Feb-Mar;129(2):141–153. [PubMed] [Google Scholar]
  34. Ray T. L., Wuepper K. D. Activation of the alternative (properdin) pathway of complement by Candida albicans and related species. J Invest Dermatol. 1976 Dec;67(6):700–703. doi: 10.1111/1523-1747.ep12598581. [DOI] [PubMed] [Google Scholar]
  35. SUMMERS D. F., GROLLMAN A. P., HASENCLEVER H. F. POLYSACCHARIDE ANTIGENS OF CANDIDA CELL WALL. J Immunol. 1964 Mar;92:491–499. [PubMed] [Google Scholar]
  36. Thong Y. H., Ferrante A. Alternative pathway of complement activation by Candida albicans. Aust N Z J Med. 1978 Dec;8(6):620–622. doi: 10.1111/j.1445-5994.1978.tb04850.x. [DOI] [PubMed] [Google Scholar]
  37. Tronchin G., Bouchara J. P., Robert R. Dynamic changes of the cell wall surface of Candida albicans associated with germination and adherence. Eur J Cell Biol. 1989 Dec;50(2):285–290. [PubMed] [Google Scholar]
  38. Wilson M. A., Kozel T. R. Contribution of antibody in normal human serum to early deposition of C3 onto encapsulated and nonencapsulated Cryptococcus neoformans. Infect Immun. 1992 Mar;60(3):754–761. doi: 10.1128/iai.60.3.754-761.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Young B. J., Kozel T. R. Effects of strain variation, serotype, and structural modification on kinetics for activation and binding of C3 to Cryptococcus neoformans. Infect Immun. 1993 Jul;61(7):2966–2972. doi: 10.1128/iai.61.7.2966-2972.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES